ATE238555T1 - Krebsbehandlung - Google Patents

Krebsbehandlung

Info

Publication number
ATE238555T1
ATE238555T1 AT99905084T AT99905084T ATE238555T1 AT E238555 T1 ATE238555 T1 AT E238555T1 AT 99905084 T AT99905084 T AT 99905084T AT 99905084 T AT99905084 T AT 99905084T AT E238555 T1 ATE238555 T1 AT E238555T1
Authority
AT
Austria
Prior art keywords
cancer treatment
cancerous
elevation
testing
cdk1
Prior art date
Application number
AT99905084T
Other languages
English (en)
Inventor
Hilmar Meek Warenius
Original Assignee
Theryte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9803447A external-priority patent/GB2334578A/en
Priority claimed from GB9803446A external-priority patent/GB2334577A/en
Priority claimed from GBGB9812151.0A external-priority patent/GB9812151D0/en
Priority claimed from GB9814545A external-priority patent/GB2334579B/en
Priority claimed from GB9903035A external-priority patent/GB2335739A/en
Application filed by Theryte Ltd filed Critical Theryte Ltd
Application granted granted Critical
Publication of ATE238555T1 publication Critical patent/ATE238555T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4748—Details p53
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
AT99905084T 1998-02-18 1999-02-18 Krebsbehandlung ATE238555T1 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB9803447A GB2334578A (en) 1998-02-18 1998-02-18 Diagnosis of cancer involving assay of levels of cyclin-dependent kinase (CDK) isoenzymes
GB9803446A GB2334577A (en) 1998-02-18 1998-02-18 Resistance of p53 mutant cancer cells to cytoxic effects of (chemo)therapeutic agents involving assay of cyclin D1 protein
GBGB9812151.0A GB9812151D0 (en) 1998-06-05 1998-06-05 Treating cancer
GB9814545A GB2334579B (en) 1998-02-18 1998-07-03 Treating cancer
GB9903035A GB2335739A (en) 1998-02-18 1999-02-10 Screening anti-cancer agents
PCT/GB1999/000503 WO1999042828A2 (en) 1998-02-18 1999-02-18 Treating cancer

Publications (1)

Publication Number Publication Date
ATE238555T1 true ATE238555T1 (de) 2003-05-15

Family

ID=27517448

Family Applications (6)

Application Number Title Priority Date Filing Date
AT99905087T ATE238557T1 (de) 1998-02-18 1999-02-18 Krebsbehandlung
AT99905086T ATE238556T1 (de) 1998-02-18 1999-02-18 Krebsbehandlung
AT99905084T ATE238555T1 (de) 1998-02-18 1999-02-18 Krebsbehandlung
AT99905083T ATE238554T1 (de) 1998-02-18 1999-02-18 Krebsbehandlung
AT99906326T ATE238558T1 (de) 1998-02-18 1999-02-18 Krebsbehandlung
AT99905082T ATE238553T1 (de) 1998-02-18 1999-02-18 Krebsbehandlung

Family Applications Before (2)

Application Number Title Priority Date Filing Date
AT99905087T ATE238557T1 (de) 1998-02-18 1999-02-18 Krebsbehandlung
AT99905086T ATE238556T1 (de) 1998-02-18 1999-02-18 Krebsbehandlung

Family Applications After (3)

Application Number Title Priority Date Filing Date
AT99905083T ATE238554T1 (de) 1998-02-18 1999-02-18 Krebsbehandlung
AT99906326T ATE238558T1 (de) 1998-02-18 1999-02-18 Krebsbehandlung
AT99905082T ATE238553T1 (de) 1998-02-18 1999-02-18 Krebsbehandlung

Country Status (8)

Country Link
US (3) US6521407B1 (de)
EP (7) EP1057028B1 (de)
JP (7) JP2002504496A (de)
AT (6) ATE238557T1 (de)
AU (8) AU741712B2 (de)
CA (7) CA2321480A1 (de)
DE (6) DE69907154T2 (de)
WO (8) WO1999042836A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69929699T2 (de) * 1998-08-14 2006-08-24 Japan Science And Technology Agency, Kawaguchi Nukleinsäure, die spezifisch an ein ras zielprotein binden kann
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ATE538794T1 (de) * 1999-01-13 2012-01-15 Bayer Healthcare Llc Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
AU2001245939A1 (en) * 2000-03-24 2001-10-08 Millennum Pharmaceuticals, Inc. Compositions and methods for the identification, assessment, prevention, and therapy of human cancers
WO2001084156A2 (en) * 2000-04-28 2001-11-08 Millennium Pharmaceuticals, Inc. Identification, assessment, prevention, and therapy of human cancers
US6905816B2 (en) 2000-11-27 2005-06-14 Intelligent Medical Devices, Inc. Clinically intelligent diagnostic devices and methods
US7371763B2 (en) * 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
US20080108672A1 (en) * 2002-01-11 2008-05-08 Bernd Riedl Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
MXPA04007832A (es) 2002-02-11 2005-09-08 Bayer Pharmaceuticals Corp Aril-ureas con actividad inhibitoria de angiogenesis.
JP2003304884A (ja) * 2002-02-13 2003-10-28 Japan Found Cancer Res 抗がん剤の適合性予測方法
GB2387385A (en) * 2002-03-25 2003-10-15 Theryte Ltd Chemotherapeutic agents for treating cancer
ES2320437T3 (es) * 2002-03-25 2009-05-22 Theryte Limited Tratamiento de canceres.
WO2003106974A2 (en) * 2002-06-18 2003-12-24 Irm Llc Diagnosis and treatment of chemoresistant tumors
US7501257B2 (en) 2003-02-26 2009-03-10 Sysmex Corporation Molecular diagnostic method of a cancer tissue or a cancer cell
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
WO2004113274A2 (en) * 2003-05-20 2004-12-29 Bayer Pharmaceuticals Corporation Diaryl ureas with kinase inhibiting activity
EA010485B1 (ru) 2003-07-23 2008-10-30 Байер Фамэсьютиклс Копэрейшн Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты)
US8021831B2 (en) * 2003-08-25 2011-09-20 Board Of Regents, The University Of Texas System Taxane chemosensitivity prediction test
US20050136177A1 (en) * 2003-08-25 2005-06-23 Anthony Hesse Method for coloring landscaping materials using foamable dry colorant
US7749698B2 (en) * 2004-02-23 2010-07-06 Novartis Ag p53 wild-type as biomarker for the treatment with mTOR inhibitors in combination with a cytotoxic agent
US20060019268A1 (en) * 2004-03-26 2006-01-26 Research Development Foundation Molecular markers of cisplatin resistance in cancer and uses thereof
US8921057B2 (en) 2004-05-31 2014-12-30 Sysmex Corporation Method of assessing properties of mammalian cells, and method of diagnosing cancer using the same
SG156625A1 (en) * 2004-12-08 2009-11-26 Aventis Pharma Inc Method for measuring resistance or sensitivity to docetaxel
US7957910B2 (en) * 2005-01-31 2011-06-07 Sysmex Corporation Method for predicting effectiveness of chemotherapy
JP4944446B2 (ja) * 2005-01-31 2012-05-30 シスメックス株式会社 抗がん剤治療の有効性予測方法
US9234897B2 (en) * 2005-03-31 2016-01-12 Two Cells Co., Ltd Method for distinguishing mesenchymal stem cell using molecular marker and use thereof
US20100279994A1 (en) * 2005-06-21 2010-11-04 Inifinity Discovery, Inc. Ansamycin Formulations and Methods of Use Thereof
JP5046574B2 (ja) * 2005-06-30 2012-10-10 シスメックス株式会社 抗がん剤治療の有効性予測方法
US7682785B2 (en) * 2005-06-30 2010-03-23 Sysmex Corporation Method for predicting effectiveness of chemotherapy using anticancer agent
JP4766969B2 (ja) 2005-09-14 2011-09-07 シスメックス株式会社 組織性質判定装置
WO2007062222A2 (en) 2005-11-22 2007-05-31 University Of South Florida Inhibition of cell proliferation
JP5111902B2 (ja) * 2007-03-14 2013-01-09 シスメックス株式会社 癌の診断支援装置
WO2008115561A2 (en) * 2007-03-21 2008-09-25 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
US20080255080A1 (en) * 2007-04-12 2008-10-16 Wright James L Hydroquinone Ansamycin Formulations
EP2028600B1 (de) 2007-08-24 2016-10-26 Sysmex Corporation Diagnose-Hilfssystem für Krebs, Diagnosehilfe für Informationen über das Krebsverfahren und Computerprogrammprodukt
GB0804496D0 (en) 2008-03-11 2008-04-16 Theryte Ltd Treating cancer
US20100184851A1 (en) * 2008-08-29 2010-07-22 University Of South Florida Inhibition of cell proliferation
WO2010045442A1 (en) 2008-10-15 2010-04-22 Infinity Discovery, Inc. Ansamycin hydroquinone compositions
WO2010135426A1 (en) * 2009-05-19 2010-11-25 Infinity Pharmaceuticals, Inc. Methods of treating liposarcoma

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK354487A (da) * 1986-07-11 1988-01-12 Noboru Yanaihara Oncogen-relaterede peptider
CA1339069C (en) * 1987-11-09 1997-07-29 Henry Lee Niman Polypeptide-induced monoclonal receptors to protein ligand
WO1991019006A1 (en) * 1990-06-01 1991-12-12 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce MONOCLONAL ANTIBODIES FOR IDENTIFICATION AND PREPARATION OF raf-1 ONCOPROTEIN
EP0665886B1 (de) * 1992-10-16 2003-06-11 Cold Spring Harbor Laboratory Umlagerung des cyclin komlexes und seine darauf bezogenen anwendungen
US5381224A (en) * 1993-08-30 1995-01-10 A. E. Dixon Scanning laser imaging system
DE4444969C1 (de) * 1994-12-16 1996-10-24 Orga Med Dr Med Erwin Klopfer Nachweis von Antikörpern gegen p53 in Körperflüssigkeiten
AU6593196A (en) * 1995-07-20 1997-02-18 Paracelsian, Inc. Determination of the presence of abnormal cellular proliferation through the detection of one or more cyclin dependent kinases
US5714329A (en) * 1995-11-29 1998-02-03 Sequana Theraputics, Inc. Methods for the diagnosis of a genetic predisposition to cancer associated with variant CDK4 allele
CA2251716A1 (en) * 1996-04-15 1997-10-23 W. Gillies Mckenna Sensitization of cells to radiation and chemotherapy
WO1997042222A1 (en) * 1996-05-08 1997-11-13 Cyclacel Limited Methods and means for inhibition of cdk4 activity
WO1998034118A1 (en) * 1997-01-30 1998-08-06 Yale University Diagnostic methods and compositions based on the distribution of rad51

Also Published As

Publication number Publication date
EP1057028B1 (de) 2003-04-23
DE69907156D1 (de) 2003-05-28
EP1057027A2 (de) 2000-12-06
AU2538299A (en) 1999-09-06
EP1057032B1 (de) 2003-04-23
US20030134315A1 (en) 2003-07-17
WO1999042839A3 (en) 1999-10-28
AU2538499A (en) 1999-09-06
JP2002504688A (ja) 2002-02-12
WO1999042828A3 (en) 2000-08-24
DE69907155T2 (de) 2004-02-05
CA2321482A1 (en) 1999-08-26
WO1999042834A2 (en) 1999-08-26
AU2630099A (en) 1999-09-06
WO1999042837A1 (en) 1999-08-26
EP1057029A2 (de) 2000-12-06
US6521407B1 (en) 2003-02-18
AU739001B2 (en) 2001-10-04
ATE238556T1 (de) 2003-05-15
CA2321467A1 (en) 1999-08-26
CA2321479A1 (en) 1999-08-26
WO1999042834A3 (en) 1999-11-25
DE69907156T2 (de) 2004-02-12
DE69907153T2 (de) 2004-01-29
AU2538199A (en) 1999-09-06
JP2002504687A (ja) 2002-02-12
EP1057028A1 (de) 2000-12-06
AU2538599A (en) 1999-09-06
ATE238557T1 (de) 2003-05-15
EP1057029B1 (de) 2003-04-23
US6878526B1 (en) 2005-04-12
CA2321481A1 (en) 1999-08-26
EP1057031A1 (de) 2000-12-06
AU743454B2 (en) 2002-01-24
WO1999042836A1 (en) 1999-08-26
CA2321438A1 (en) 1999-08-26
CA2321458A1 (en) 1999-08-26
JP2002504496A (ja) 2002-02-12
ATE238553T1 (de) 2003-05-15
EP1057033B1 (de) 2003-04-23
AU741712B2 (en) 2001-12-06
CA2321480A1 (en) 1999-08-26
DE69907154T2 (de) 2004-02-19
JP2002504683A (ja) 2002-02-12
DE69907152D1 (de) 2003-05-28
WO1999042821A3 (en) 1999-11-11
EP1057030B1 (de) 2003-04-23
AU741632B2 (en) 2001-12-06
JP2002504354A (ja) 2002-02-12
WO1999042821A2 (en) 1999-08-26
ATE238554T1 (de) 2003-05-15
EP1057032A2 (de) 2000-12-06
DE69907153D1 (de) 2003-05-28
WO1999042839A2 (en) 1999-08-26
JP2002503822A (ja) 2002-02-05
JP2002504353A (ja) 2002-02-12
AU2538099A (en) 1999-09-06
ATE238558T1 (de) 2003-05-15
WO1999042090A3 (en) 1999-11-04
WO1999042090A2 (en) 1999-08-26
DE69907154D1 (de) 2003-05-28
EP1057033A1 (de) 2000-12-06
WO1999042835A1 (en) 1999-08-26
AU735896B2 (en) 2001-07-19
AU749180B2 (en) 2002-06-20
AU2537999A (en) 1999-09-06
EP1057031B1 (de) 2003-04-23
AU2630199A (en) 1999-09-06
DE69907151D1 (de) 2003-05-28
EP1057030A2 (de) 2000-12-06
WO1999042828A2 (en) 1999-08-26
AU753588B2 (en) 2002-10-24
DE69907155D1 (de) 2003-05-28

Similar Documents

Publication Publication Date Title
DE69907153D1 (de) Krebsbehandlung
ATE194660T1 (de) Veraendertes gen bei menschlichem colorektalem- krebs
BRPI9912227B1 (pt) método para diagnóstico precoce in vitro de carcinomas e de seus estágios iniciais e kit para realização do método.
AU4085097A (en) Methods and kits for obtaining and assaying mammary fluid samples for breast diseases, including cancer
EP1035215A3 (de) Verfahren und Sondenset zur Erkennung von Krebs
AU2001253079A1 (en) Methods, compositions and kits for the detection and monitoring of breast cancer
AU7868300A (en) Prostate cancer marker proteins
AU2002315411A1 (en) Detection and treatment of prostate cancer
ATE277352T1 (de) Einetenascin-c isoform als marker für neoplasmen
WO2002023200A3 (en) Human breast cancer biomarkers
PT1295125E (pt) Teste imunologico e kit diagnostico para adenocarcinoma da prostata
AU2001294165A1 (en) Apparatus for prostate cancer diagnose
WO2003058198A3 (en) Human breast cancer biomarkers
WO2006023382A3 (en) Collagen vi and cancer
WO1997030354A3 (en) Foetal cell analysis
DE60216045D1 (de) Krebsdiagnoseverfahren
AU2003299352A8 (en) Method for analyzing tumor agressivity comprising measurement of polymerized actin
UA42589A (uk) Спосіб діагностики гомеостазу
UA36444A (uk) Спосіб діагностики активності патологічного процесу у хворих на обмежену склеродермію
UA70269A (en) Method of the preoperational differential diagnosis of the benign and malignant tumors of the thyroid gland

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties